The -844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis

Rheumatology International

Volumn 28, Issue 4, 2008, Pages 355-360

  Torres Carrillo, Nora Magdalena ^a   Torres Carrillo, Norma ^a   Vázquez Del Mercado, Mónica ^a   Delgado Rizo, Vidal ^a   Oregón Romero, Edith ^a   Parra Rojas, Isela ^b   Muñoz Valle, José Francisco ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE GUERRERO   (Mexico)

Author keywords

Plasminogen activator inhibitor 1; Polymorphism; Real time PCR; Rheumatoid arthritis

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEMATOLOGICAL PARAMETERS; HEREDITY; HETEROZYGOTE; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS;

EID: 38049065428     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0453-z     Document Type: Article

References (27)

1. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356-361
2. Firestein GS (2005) Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11:S39-S44
3. Pope RM (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2:1-9
4. Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Res 45:101-106
5. Gils A, Declerck PJ (2004) Plasminogen activator inhibitor-1. Curr Med Chem 11:2323-2334
6. Agirbasli M (2005) Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 59:102-106
7. Busso N, Péclat V, So A, Sappino AP (1997) Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56:550-557
8. Ruiz-Quezada S, Vázquez-Del Mercado M, Parra-Rojas I, Rangel-Villalobos H, Best-Aguilera C, Sánchez-Orozco LV, Muñoz-Valle JF (2004) Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Ann Genet 47:155-162
9. Grubic N, Stegnar M, Peternel P, Kaider A, Binder BR (1996) A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 84:431-443
10. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I (1997) Five frequent polymorphisms of the PAI-1 gene lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17:851-858
11. Morange PE, Henry M, Tregouët D, Granel B, Aillaud MF, Alessi MC, Juhan-Vague I (2000) The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 20:1387-1391
12. Lopes C, Dina C, Durand E, Froguel P (2003) PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 46:1284-1290
13. Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I (1998) Metabolic determinations are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations. A family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 18:84-91
14. Lu F, Hong J, Kening S, Cuili Z, Jingxia S, Yonglin H (2001) Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction. Chin Med J 114:266-269
15. (-844)G promoter polymorphism on the risk and extent of coronary heart disease. Thromb Haemost 88:697-698
16. Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon-Segovia D (1993) How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol 11:117-121
17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
18. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
19. Vázquez-Del Mercado M, Delgado-Rizo V, Muñoz-Valle JF, Orozco-Alcalá J, Volk HD, Armendáriz-Borunda J (1999) Expression of interleukin-1β, tumor necrosis factor α, interleukins-6, -10 and -4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid artritis patients. Clin Exp Rheumatol 17:575-583
20. H2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol 131:377-384
21. Fabbro D, Délia AV, Spizzo R, Driul L, Barillari G, Di Loreto C, Marcheson D (2003) Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest 56:17-22
22. Smolarz B, Blasiak J, Kulig A, Romanowicz-Makowska H, Ulanska J, Pander B, Szewczyk T (2001) Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res 20:247-252
23. Keene JD (2001) Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc Natl Acad Sci USA 98:7018-7024
24. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916
25. Svenson KLG, Lithell H, Hallgren R, Vessby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 147:1917-1920
26. Wallace DJ (1994) Antimalarial agents and lupus. In systemic lupus erythematosus. Dis Clin North Am 20:243-263
27. Nodis HN, Quismorio FP, Wickham E, Blankenhorn DH (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxyl-chloroquine in patients with systemic lupus erythematosus. J Rheumatol 20:661-665